ArticleHealth research policy and systems2013
Health policy and systems research in access to medicines: a prioritized agenda for low- and middle-income countries.
Article in Health research policy and systems, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Pooled it
- How are health research priorities set in low and middle income countries? A systematic review of published reports.PloS one · 2014Pooled it
- Health technology assessment in sub-Saharan Africa: a descriptive analysis and narrative synthesis.Cost effectiveness and resource allocation : C/E · 2021Article
- Ethical Dimensions of Public Health Actions and Policies With Special Focus on COVID-19.Frontiers in public health · 2021Review
- Understanding the implications of the Sustainable Development Goals for health policy and systems research: results of a research priority setting exercise.Globalization and health · 2020Article
- Identifying health policy and systems research priorities on multisectoral collaboration for health in low-income and middle-income countries.BMJ global health · 2018Article
- 'Knowledge for better health' revisited - the increasing significance of health research systems: a review by departing Editors-in-Chief.Health research policy and systems · 2017Article
- Health systems research on access to medicines: unpacking challenges in implementing policies in the face of the epidemiological transition.BMJ global health · 2017Article
- Enhancing evidence informed policymaking in complex health systems: lessons from multi-site collaborative approaches.Health research policy and systems · 2016Article
- Strategies and Systems-Level Interventions to Combat or Prevent Drug Counterfeiting: A Systematic Review of Evidence Beyond Effectiveness.Pharmaceutical medicine · 2016Review
- Advancing the field of health systems research synthesis.Systematic reviews · 2015Review
- Stakeholders' perspectives on access-to-medicines policy and research priorities in Latin America and the Caribbean: face-to-face and web-based interviews.Health research policy and systems · 2014Article
- The Effect of China's National Essential Medicine Policy on Health Expenses: Evidence From a National Study.Inquiry : a journal of medical care organization, provision and financingArticle
- Improving access to medicines to reduce marketing and use of substandard and falsified medicines in Africa: Scoping review.The journal of medicine accessArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify priority policy issues in access to medicines (ATM) relevant for low- and middle-income countries, to identify research questions that would help address these policy issues, and to prioritize these research questions in a health policy and systems research (HPSR) agenda.
methodsThe study involved i) country- and regional-level priority-setting exercises performed in 17 countries across five regions, with a desk review of relevant grey and published literature combined with mapping and interviews of national and regional stakeholders; ii) interviews with global-level stakeholders; iii) a scoping of published literature; and iv) a consensus building exercise with global stakeholders which resulted in the formulation and ranking of HPSR questions in the field of ATM.
resultsA list of 18 priority policy issues was established following analysis of country-, regional-, and global-level exercises. Eighteen research questions were formulated during the global stakeholders' meeting and ranked according to four ranking criteria (innovation, impact on health and health systems, equity, and lack of research). The top three research questions were: i) In risk protection schemes, which innovations and policies improve equitable access to and appropriate use of medicines, sustainability of the insurance system, and financial impact on the insured? ii) How can stakeholders use the information available in the system, e.g., price, availability, quality, utilization, registration, procurement, in a transparent way towards improving access and use of medicines? and iii) How do policies and other interventions into private markets, such as information, subsidies, price controls, donation, regulatory mechanisms, promotion practices, etc., impact on access to and appropriate use of medicines?
conclusionsOur HPSR agenda adopts a health systems perspective and will guide relevant, innovative research, likely to bear an impact on health, health systems and equity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.